RxDoctor Payments Data

Jason Stern, DO

Hematology & Oncology · Mayfield Hts, OHNPI 1215005319

Payments from drug & device makers

$4,584in general payments, 2019–2025

Across 33 payments — averaging $138.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • GSK$672
  • Incyte Corporation$200
  • Takeda Pharmaceuticals U.S.A., Inc.$110
  • Astellas Pharma US Inc$100
  • Dova Pharmaceuticals$94
  • plus $592 from 16 others

What the payments were for

  • Consulting fees$3,46075%
  • Food & beverage$73416%
  • Education$3909%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,584 in reported general payments places this provider in the 45th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$51,738
Medicare patients
206
Services billed
519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide20$275,768
BrukinsaZanubrutinib13$184,498
EliquisApixaban34$23,628
Anastrozole83$1,439
Tamoxifen Citrate22$1,127
Acyclovir35$754
Fluconazole13$485
Letrozole22$456
Hydroxyurea23$340
Ondansetron Hcl17$332
Dexamethasone17$323
Prochlorperazine Maleate15$176
Pantoprazole Sodium11$119
Potassium Chloride12$119
Prednisone26$93

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$100$275,76820 claims
PfizerEliquis$21$23,62834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Mayfield Hts

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →